Rheumatoid arthritis
Conditions
Interventions
Treatment group:Colquhounia root tablets combined with iguratimod
Control group:Iguratimod
Sponsors
The First Affiliated Hospital of Henan University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Those who meet the 2010 ACR/EULAR classification standards; (2) After X-ray shooting, the grade is determined to be grade I-III according to the grading standards for joint dysfunction; (3) The patient gave informed consent to this study and signed the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Heart, liver, kidney dysfunction or joint lesions that may be caused by cardiovascular and cerebrovascular diseases; (2) Pregnant women, lactating women and women with fertility needs during treatment; (3) Persons with mental illness or those who have taken drugs for mental illness in the near future; (4) Patients with allergies and those who are allergic to the drugs used in this study; (5) Active peptic ulcer/bleeding, or previous recurrent ulceration/bleeding; (6) Bone marrow hematopoietic disorders, severe anemia, low white blood cells, platelets.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual analogue scale, erythrocyte sedimentation rate, c-reactive protein, Disease Activity Score 28; | — |
Secondary
| Measure | Time frame |
|---|---|
| Rheumatoid factor, morning stiffness time, number of tender joints, number of swollen joints, grip strength; | — |
Countries
China
Contacts
Public ContactZihua Wang
The First Affiliated Hospital of Henan University of Chinese Medicine
Outcome results
None listed